Discovery & Development Europe 2027 brings together a curated ecosystem of over 1,000 senior leaders from pharma, biotech, academia, and technology organizations to address the critical issues shaping the future of drug discovery, development, and delivery. The event covers the entire R&D journey, featuring co-located programs on Drug Discovery, Formulation…
Programmed at Discovery, in alphabetical order.
The companies behind the program. Tiers as disclosed.
Selected from 51 sessions.
Oncology leads the way in genome-based medicine with estimates of at least 90 FDA approvals requiring biomarkers for optimal patient selection – almost half of all drugs authorized…
Brain health conditions affect 1 in 3 Europeans, costing €430bn annually - yet many are preventable and underfunded. Innovative therapies and cross-sector partnerships are accelera…
The presentation will discuss the challenges and opportunities in formulating biologics. In particular, it will focus on the use of ionic liquids to address bioavailability and sol…
The phrase “Lab-in-the-loop” is an often-used term. But what does it really mean? How far along are we on our journey towards autonomous science? This presentation will focus on ho…
Industry Presentation • During lead optimization, PBPK models incorporating human in vitro parameters can predict the oral bioavailability of drugs, if the mechanisms limiting the …
The size of the virtually explorable chemical space is expanding due to the application of novel digital workflows. Effective selection of quality monomers, scalable information en…
The size of the virtually explorable chemical space is expanding due to the application of novel digital workflows. Effective selection of quality monomers, scalable information en…
IAM1363 is a potential best-in-class type II HER2 inhibitor with broad activity across HER2 mutants, >5,000-fold selectivity over EGFR, preferential tumor enrichment, and robust br…
• During lead optimization, PBPK models incorporating human in vitro parameters can predict the oral bioavailability of drugs, if the mechanisms limiting the oral exposure of a dru…
An audience of 30 companies, parsed from the program.
The numbers below are derived from the speakers, sponsors, and exhibitors on this page, cross-referenced into one ledger. They are the only thing here that 10times.com cannot tell you.